Literature DB >> 18024052

Population pharmacokinetics of micafungin in adult patients.

Tawanda Gumbo1, John Hiemenz, Lei Ma, James J Keirns, Donald N Buell, George L Drusano.   

Abstract

We performed population pharmacokinetic analysis of micafungin in adult patients treated with doses between 12.5 and 200 mg/day. Our analysis identified a breakpoint patient weight of 66.3 kg above which serum clearance increased by approximately 50%. Patients with weight >66.3 kg may need larger doses to achieve similar exposures to those <66.3 kg. However, the clinical implications are still unknown.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18024052     DOI： 10.1016/j.diagmicrobio.2007.09.018

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  26 in total

1.  Clinical pharmacodynamic index identification for micafungin in esophageal candidiasis: dosing strategy optimization.

Authors:  David R Andes; Daniel K Reynolds; Scott A Van Wart; Alexander J Lepak; Laura L Kovanda; Sujata M Bhavnani
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

Review 2.  Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies.

Authors:  David J Epstein; Susan K Seo; Janice M Brown; Genovefa A Papanicolaou
Journal:  J Antimicrob Chemother       Date:  2018-01-01       Impact factor: 5.790

3.  Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patients.

Authors:  Thomas J Walsh; Sylvain Goutelle; Roger W Jelliffe; Jeffrey A Golden; Emily A Little; Catherine DeVoe; Diana Mickiene; Maggie Hayes; John E Conte
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

4.  Redefining multidrug-resistant tuberculosis based on clinical response to combination therapy.

Authors:  Tawanda Gumbo; Jotam G Pasipanodya; Peter Wash; André Burger; Helen McIlleron
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

5.  In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.

Authors:  D Andes; D J Diekema; M A Pfaller; J Bohrmuller; K Marchillo; A Lepak
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

6.  Pharmacokinetic/Pharmacodynamic Background and Methods and Scientific Evidence Base for Dosing of Second-line Tuberculosis Drugs.

Authors:  Tawanda Gumbo; Jan-Willem C Alffenaar
Journal:  Clin Infect Dis       Date:  2018-11-28       Impact factor: 9.079

Review 7.  Echinocandin antifungal drugs in fungal infections: a comparison.

Authors:  Sharon C-A Chen; Monica A Slavin; Tania C Sorrell
Journal:  Drugs       Date:  2011-01-01       Impact factor: 9.546

8.  Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts.

Authors:  Susan J Howard; Joanne Livermore; Andrew Sharp; Joanne Goodwin; Lea Gregson; A Alastruey-Izquierdo; D S Perlin; Peter A Warn; William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2011-08-01       Impact factor: 5.191

9.  Weight drives caspofungin pharmacokinetic variability in overweight and obese people: fractal power signatures beyond two-thirds or three-fourths.

Authors:  Ronald G Hall; Mark A Swancutt; Claudia Meek; Richard Leff; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

10.  In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.

Authors:  D R Andes; D J Diekema; M A Pfaller; K Marchillo; J Bohrmueller
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.